(10 days)
PMA P850088/S36
PMA P850088/S36
No
The device description and performance studies focus on the chemical and biological properties of the neutralizing tablets, with no mention of AI or ML.
No.
The ULTRACARE Neutralizing Tablets are used to neutralize a disinfecting solution for contact lenses, which is a maintenance function, not a direct therapeutic treatment for a disease or condition.
No
Explanation: The device is a neutralizing tablet for contact lens disinfecting solution, not a tool for diagnosing medical conditions.
No
The device is a physical tablet containing chemical components, not software.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for neutralizing a disinfecting solution used for contact lenses. This is a product used on a medical device (contact lenses) and for the user of that medical device, not for diagnosing a condition or analyzing a biological sample from a human body.
- Device Description: The description details the chemical composition of a tablet designed to neutralize a solution. This aligns with a cleaning/disinfecting accessory for a medical device.
- Performance Studies: The studies focus on lens compatibility, microbiology (efficacy against microorganisms on the lens), and toxicology (safety for the eye when used with the lens). These are relevant to a contact lens care product, not an IVD.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples, diagnosing diseases, or providing information about a patient's health status.
Therefore, the ULTRACARE Neutralizing Tablets are a medical device accessory for contact lenses, not an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
ULTRACARE Neutralizing Tablets are part of the ULTRACARE System, a disinfecting, neutralizing and storage system for daily and extended wear soft (hydrophilic) contact lenses in a chemical (not heat) lens care system.
The ULTRACARE Neutralizing Tablets are indicated for use to neutralize the ULTRACARE Disinfecting Solution in the ULTRACARE System. ULTRACARE Neutralizing Tablets are added at the beginning of the disinfection cycle so that disinfection and neutralization occur without any additional steps.
Product codes
86 LPN
Device Description
ULTRACARE Neutralizing Tablets are smooth, round, beige to pale pink tablets that contain catalase, hydroxypropyl methylcellulose, and cyanocobalamin (Vitamin B12) as a color indicator, with buffering and tableting agents.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Preclinical Testing:
A series of in-vitro and in-vivo preclinical chemical, microbiological and toxicological studies were performed to assess the safety and effectiveness of ULTRACARE Neutralizing Tablets. The results of these studies indicate that ULTRACARE Neutralizing Tablets are substantially equivalent to the predicate device.
Lens compatibility:
A study was conducted to determine the compatibility of hydrogel contact lenses with the ULTRACARE lens care regimen consisting of ULTRACARE Disinfecting Solution, ULTRACARE Neutralizing Tablets and ULTRAZYME Enzymatic Cleaner. A control regimen using the predicate device was also tested.
Representative lenses from FDA Lens Groups 1 and 4 were monitored for changes in power, diameter, basecurve, spectral transmittance and material surface changes during and after 30 regimen cycles.
The results indicated that ULTRACARE Neutralizing Tablets used in combination with ULTRACARE Disinfecting Solution and ULTRAZYME Enzymatic Cleaner are compatible with hydrogel contact lenses and perform comparably to the predicate device.
Microbiology:
The antimicrobial efficacy of the ULTRACARE System using ULTRACARE Neutralizing Tablets was evaluated, in the presence and absence of ULTRAZYME Enzymatic Cleaner, against FDA’s recommended panel of microorganisms.
The test results showed that the disinfection system using ULTRACARE Neutralizing Tablets met the criteria for "stand-alone" contact lens disinfecting products.
Toxicology:
A 28-day subacute ocular safety study was performed using ULTRACARE Neutralizing Tablets in conjunction with ULTRACARE Disinfecting Solution and ULTRAZYME Enzymatic Cleaner. The results of this study showed no clinically significant ocular discomfort, irritation or toxicity.
Clinical Testing:
A three-month clinical study was conducted to evaluate the safety and acceptability of ULTRACARE Neutralizing Tablets when used with ULTRACARE Disinfecting Solution for hydrogel contact lenses. The results of the study showed that the ULTRACARE lens care regimen is safe and acceptable for its intended use based on:
- Successful use by 96.7% (55/59) of evaluable subjects.
- No apparent difference in the key safety variable of corneal staining compared to the predicate device
- No apparent difference in the key acceptability variable of lens comfort compared to the predicate device.
Results of the clinical study demonstrate the safety, acceptability and substantial equivalence of ULTRACARE Neutralizing Tablets to the predicate device for its intended use.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Successful use by 96.7% (55/59) of evaluable subjects.
Predicate Device(s)
ULTRACARE® Neutralizing Tablet with Color Indicator
Reference Device(s)
PMA P850088/S36
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 886.5928 Soft (hydrophilic) contact lens care products.
(a)
Identification. A soft (hydrophilic) contact lens care product is a device intended for use in the cleaning, rinsing, disinfecting, lubricating/rewetting, or storing of a soft (hydrophilic) contact lens. This includes all solutions and tablets used together with soft (hydrophilic) contact lenses and heat disinfecting units intended to disinfect a soft (hydrophilic) contact lens by means of heat.(b)
Classification. Class II (Special Controls) Guidance Document: “Guidance for Industry Premarket Notification (510(k)) Guidance Document for Contact Lens Care Products.”
0
2525 Dupont Drive, P.O. Box 19534, Irvine, California, USA 92623-9534 Telephone: (714) 246-4500 Website: www.allergan.com
Image /page/0/Picture/3 description: The image shows a black and white abstract design. The design consists of several horizontal lines of varying lengths, stacked vertically. The lines are thicker in the middle and taper towards the ends, creating a rounded, capsule-like shape for each line. The overall arrangement of the lines forms a symmetrical, somewhat oval or diamond-like pattern.
K 98 4383
December 4. 1998
510(k) SUMMARY
Submitter Information 1.
Allergan 2525 Dupont Drive Irvine, California 92612
| Contact Person: | Paul J. Nowacki |
|---|---|
| Manager, Regulatory Affairs |
Telephone Number: (714) 246-6761
Device Name 2.
| Classification Name: | Soft (hydrophilic) contact lens care products |
|---|---|
| Proprietary Name | ULTRACARE® Neutralizing Tablets |
Predicate Device 3.
The predicate device is ULTRACARE® Neutralizing Tablet with Color Indicator.
Description of the Device 4.
ULTRACARE Neutralizing Tablets are smooth, round, beige to pale pink tablets that contain catalase, hydroxypropyl methylcellulose, and cyanocobalamin (Vitamin B12) as a color indicator, with buffering and tableting agents.
ਨੰ Indications for Use
ULTRACARE Neutralizing Tablets are part of the ULTRACARE® System, a disinfecting, neutralizing and storage system for daily and extended wear soft (hydrophilic) contact lenses in a chemical (not heat) lens care system.
The ULTRACARE Neutralizing Tablets are indicated for use to neutralize the ULTRACARE® Disinfecting Solution in the ULTRACARE System. ULTRACARE Neutralizing Tablets are added at the beginning of the disinfection cycle so that disinfection and neutralization occur without any additional steps.
1
Description of Safety and Substantial Equivalence 6.
A series of preclinical tests and clinical testing was performed to demonstrate the safety and effectiveness of ULTRACARE® Neutralizing Tablets. The tests were designed and performed in accordance with the guidelines set forth in FDA's May 1, 1997 Guidance for Industry - Premarket Notification [510(k)] Guidance Document for Contact Lens Care Products. The following is a summary of the test results.
Preclinical Testing
A series of in-vitro and in-vivo preclinical chemical, microbiological and toxicological studies were performed to assess the safety and effectiveness of ULTRACARE Neutralizing Tablets. The results of these studies indicate that ULTRACARE Neutralizing Tablets are substantially equivalent to the predicate device.
Lens compatibility
A study was conducted to determine the compatibility of hydrogel contact lenses with the ULTRACARE® lens care regimen consisting of ULTRACARE® Disinfecting Solution, ULTRACARE® Neutralizing Tablets and ULTRAZYME® Enzymatic Cleaner. A control regimen using the predicate device was also tested.
Representative lenses from FDA Lens Groups 1 and 4 were monitored for changes in power, diameter, basecurve, spectral transmittance and material surface changes during and after 30 regimen cycles.
The results indicated that ULTRACARE Neutralizing Tablets used in combination with ULTRACARE Disinfecting Solution and ULTRAZYME Enzymatic Cleaner are compatible with hydrogel contact lenses and perform comparably to the predicate device.
Microbiology
The antimicrobial efficacy of the ULTRACARE® System using ULTRACARE Neutralizing Tablets was evaluated, in the presence and absence of ULTRAZYME Enzymatic Cleaner, against FDA's recommended panel of microorganisms.
The test results showed that the disinfection system using ULTRACARE Neutralizing Tablets met the criteria for "stand-alone" contact lens disinfecting products.
2
Toxicology
A 28-day subacute ocular safety study was performed using ULTRACARE® Neutralizing Tablets in conjunction with ULTRACARE® Disinfecting Solution and ULTRAZYME® Enzymatic Cleaner. The results of this study showed no clinically significant ocular discomfort, irritation or toxicity.
Clinical Testing
A three-month clinical study was conducted to evaluate the safety and acceptability of ULTRACARE Neutralizing Tablets when used with ULTRACARE Disinfecting Solution for hydrogel contact lenses.. The results of the study showed that the ULTRACARE lens care regimen is safe and acceptable for its intended use based on:
- Successful use by 96.7% (55/59) of evaluable subjects .
- No apparent difference in the key safety variable of corneal staining compared . to the predicate device
- No apparent difference in the key acceptability variable of lens comfort . compared to the predicate device.
Results of the clinical study demonstrate the safety, acceptability and substantial equivalence of ULTRACARE Neutralizing Tablets to the predicate device for its intended use.
7. Substantial Equivalence
ULTRACARE Neutralizing Tablets are substantially equivalent in terms of actions, indications for use, safety, and effectiveness to the predicate device: ULTRACARE Neutralizing Tablets with Color Indicator (approved for marketing under PMA P850088/S36).
3
Image /page/3/Picture/1 description: The image shows the seal of the Department of Health & Human Services-USA. The seal features a stylized image of an eagle with three lines representing its wings. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES-USA" are arranged in a circular pattern around the eagle.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
DEC 1 8 1998
Mr. Paul J. Nowacki Manager, Regulatory Affairs Allergan 2525 Dupont Drive P.O. Box 19534 Irvine, CA 92623-9534
Re: K984383 Trade Name: ULTRACARE ® Neutralizing Tablets with Color Indicator Regulatory Class: II Product Code: 86 LPN Dated: December 4, 1998 Received: December 8, 1998
Dear Mr. Nowacki:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations .
4
Page 2 - Mr. Paul J. Nowacki
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4613. Additionally, for questions on.the.promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".
Sincerely yours,
A Roerl rosenthal
A. Ralph Rosenthal, M.D. Director Division of Ophthalmic Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
Attachment 2
Indications for Use Statement
・
:
| 510(k)
Number
(if known) | The predicate device, ULTRACARE® Neutralizing Tablets with
Color Indicator, was approved under PMA P850088/S36. |
|--------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Device Name | ULTRACARE® Neutralizing Tablets |
| Indications
For Use | ULTRACARE Neutralizing Tablets are part of the ULTRACARE
System, a disinfecting, neutralizing and storage system for daily and
extended wear soft (hydrophilic) contact lenses in a chemical (not
heat) lens care system.
The ULTRACARE Neutralizing Tablets are indicated for use to
neutralize the ULTRACARE Disinfecting Solution in the
ULTRACARE System. ULTRACARE Neutralizing Tablets are added
at the beginning of the disinfection cycle so that disinfection and
neutralization occur without any additional steps. |
PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED
Concurrence of CDRH, Office of Device Evaluation (ODE)
| (Division Sign-Off) | |
|---|---|
| Division of Ophthalmic Devices | |
| 510(k) Number | K984383 |
Prescription Use ____ (Per 21 CFR 801.109) OR Over-The-Counter Use X